Erratum: Successful Treatment of Chronic Hepatitis C Virus Infection with Sofosbuvir and Ledipasvir in Renal Transplant Recipients (Transplantation (2017) 101 (980-986) DOI: 10.1097/TP.0000000000001414);Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients

Transplantation

Volumn 101, Issue 5, 2017, Pages 980-986

  Eisenberger, Ute ^a   Guberina, Hana ^a   Willuweit, Katharina ^a   Bienholz, Anja ^a   Kribben, Andreas ^a   Gerken, Guido ^a   Witzke, Oliver ^a   Herzer, Kerstin ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; LEDIPASVIR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISOLONE; SOFOSBUVIR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE;

ADULT; AGED; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; FEMALE; GRAFT RECIPIENT; HEADACHE; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MALE; NAUSEA; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROTEINURIA; RETROSPECTIVE STUDY; REVIEW; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; FOLLOW UP; HEPATITIS C, CHRONIC; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84982796271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000002390     Document Type: Erratum

References (43)

1. Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165-1171.
2. CorougeM, Vallet-Pichard A, Pol S. HCVand the kidney. Liver Int. 2016;36 (Suppl 1):28-33.
3. Su FH, Su CT, Chang SN, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60: 553-560.
4. Kamar N, Ribes D, Izopet J, et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation. 2006;82:853-856.
5. Carbone M, Mutimer D, Neuberger J. Hepatitis C virus and nonliver solid organ transplantation. Transplantation. 2013;95:779-786.
6. Fabrizi F. Hepatitis C virus infection and dialysis: 2012 update. ISRN Nephrol. 2013;2013:159760.
7. Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495-1502.
8. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
9. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renalreplacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745-750.
10. Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre-and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2:563-575.
11. Kahraman A, Witzke O, Scherag A, et al. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol. 2011;75:16-25.
12. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19: 601-607.
13. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essentialmixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47: 618-623.
14. LeeMH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469-477.
15. Saxena V, Terrault NA. Treatment of hepatitis C infection in renal transplant recipients: the long wait is over. Am J Transplant. 2016;16:1345-1347.
16. Gordon CE, Francis J. Hepatitis C treatment in dialysis patients: is a new dawn approaching? Am J Kidney Dis. 2014;64:178-180.
17. Sawinski D, BloomRD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015;99:2458-2466.
18. Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426-1431.
19. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008;14(Suppl 2):S58-S66.
20. Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol. 2016 pii: ASN.2016010030.
21. Herzer K, Papadopoulos-Kohn A, Achterfeld A, et al. Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol. 2015;7:1287-1296.
22. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
23. Nazario HE, NdunguM,Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 mL/min. Liver Int. 2016 ;36:798-801.
24. Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-1595.
25. Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-1479.
26. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
27. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl JMed. 2014;370:1889-1898.
28. Höner Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62:561-567.
29. Ascha MS, Ascha ML, Hanouneh IA. Management of immunosuppressant agents following liver transplantation: less is more. World J Hepatol. 2016;8:148-161.
30. Oo YH, Dudley T, Nightingale P, et al. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl. 2008;14:81-87.
31. Jadoul M, Horsmans Y. Towards eradication of hepatitis C virus from dialysis units. Lancet. 2015;386:1514-1515.
32. Kidney Disease: Improving Global Outcomes (KDiGO). KDiGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008: S1-S99.
33. Reese PP, Abt PL, Blumberg EA, et al. Transplanting hepatitis C-positive kidneys. N Engl JMed. 2015;373:303-305.
34. Cosconea S, Fontaine H,Méritet JF, et al. Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. J Hepatol. 2012;57:55-60.
35. Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238-1246.
36. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144-3160.
37. D'Ambrosio R, Aghemo A, Colombo M. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert Opin Drug Saf. 2015; 14:473-484.
38. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64:790-799.
39. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.
40. Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40-47.
41. Pockros P. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. J Hepatol. 2015:257.
42. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatmentnaive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.
43. Yu TM, Lin CC, Shu KH, et al. Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: a nationwide population-based cohort study. Sci Rep. 2016;6:21312.